Javascript must be enabled to continue!
RTHP-35. RE-IRRADIATION USING PULSED REDUCED DOSE RATE RADIATION THERAPY IN PATIENTS WITH GRADE 2 GLIOMAS
View through CrossRef
Abstract
BACKGROUND
The time course of progressive grade 2 glioma can span nearly a decade. However, much less is known about re-irradiation in this cohort than in high grade patients. Pulsed reduced dose rate (PRDR) radiation therapy is a method of radiation delivery, which may spare normal tissues by slowing the rate of radiation delivery to allow repair.
METHODS
We identified consecutive patients from an institutional database initially diagnosed with grade 2 glioma from 2001 to 2017 who underwent pulsed reduced dose rate radiation therapy. Radiation was delivered in 20 cGy pulses every three minutes, most commonly with a 3D conformal, three field technique, encompassing gross disease with a 1–2 cm margin. Kaplan Meier method was utilized to analyze patient outcomes.
RESULTS
35 patients with grade 2 glioma were identified. The median survival from the date of the first surgery was 103 months (95% CI 78–129 mo). 71% underwent at least a second resection and 86% of patients receiving chemotherapy. 80% of patients underwent transformation to grade 3 (51%) or grade 4 (29%) glioma. Overall survival from PRDR was 9.8 months (95% CI 4.5–14.5mo) and progression free survival was 6.2 months (95% CI 5.1–7.4) in all patients. Overall response rate was 37%. In patients who remained grade 2 histology, overall survival was 13.3 months and two patients remain disease free at 83 and 34 months with overall response of 71%. Four seizures were documented, otherwise treatment was well tolerated.
CONCLUSIONS
Progressive grade 2 glioma can progress and evolve over nearly the course of a decade. This study demonstrates the efficacy of re-irradiation in prolonging survival in these patients by delaying progression. In patients who remain with grade 2 disease, prolonged salvage of their disease appears possible.
Title: RTHP-35. RE-IRRADIATION USING PULSED REDUCED DOSE RATE RADIATION THERAPY IN PATIENTS WITH GRADE 2 GLIOMAS
Description:
Abstract
BACKGROUND
The time course of progressive grade 2 glioma can span nearly a decade.
However, much less is known about re-irradiation in this cohort than in high grade patients.
Pulsed reduced dose rate (PRDR) radiation therapy is a method of radiation delivery, which may spare normal tissues by slowing the rate of radiation delivery to allow repair.
METHODS
We identified consecutive patients from an institutional database initially diagnosed with grade 2 glioma from 2001 to 2017 who underwent pulsed reduced dose rate radiation therapy.
Radiation was delivered in 20 cGy pulses every three minutes, most commonly with a 3D conformal, three field technique, encompassing gross disease with a 1–2 cm margin.
Kaplan Meier method was utilized to analyze patient outcomes.
RESULTS
35 patients with grade 2 glioma were identified.
The median survival from the date of the first surgery was 103 months (95% CI 78–129 mo).
71% underwent at least a second resection and 86% of patients receiving chemotherapy.
80% of patients underwent transformation to grade 3 (51%) or grade 4 (29%) glioma.
Overall survival from PRDR was 9.
8 months (95% CI 4.
5–14.
5mo) and progression free survival was 6.
2 months (95% CI 5.
1–7.
4) in all patients.
Overall response rate was 37%.
In patients who remained grade 2 histology, overall survival was 13.
3 months and two patients remain disease free at 83 and 34 months with overall response of 71%.
Four seizures were documented, otherwise treatment was well tolerated.
CONCLUSIONS
Progressive grade 2 glioma can progress and evolve over nearly the course of a decade.
This study demonstrates the efficacy of re-irradiation in prolonging survival in these patients by delaying progression.
In patients who remain with grade 2 disease, prolonged salvage of their disease appears possible.
Related Results
RTHP-37. RE-IRRADIATION OF GLIOMATOSIS CEREBRI WITH WHOLE BRAIN PULSED REDUCED DOSE RATE RE-IRRADIATION
RTHP-37. RE-IRRADIATION OF GLIOMATOSIS CEREBRI WITH WHOLE BRAIN PULSED REDUCED DOSE RATE RE-IRRADIATION
Abstract
BACKGROUND
Gliomatosis cerebri was removed from the 2016 WHO classification but the clinical problem of gliomatosis rem...
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
Background
Gliomas are the most common primary central nervous system tumors, of which the malignant gliomas account for 60%–75%. The primary and secondary brain malign...
Radiation Evaluation System for Radiation Releasing Environment of Nuclear Power Plant Based on Domain-Driven Design
Radiation Evaluation System for Radiation Releasing Environment of Nuclear Power Plant Based on Domain-Driven Design
In order to meet the sustainable development demand for energy, developing nuclear power actively has become an important means for the country to improve energy supply pattern and...
SURG-05. EXPERIENCE PROFILING OF FLUORESCENCE-GUIDED SURGERY FOR GLIOMAS
SURG-05. EXPERIENCE PROFILING OF FLUORESCENCE-GUIDED SURGERY FOR GLIOMAS
Abstract
Numerous studies reported a usefulness of 5-ALA fluorescence-guided surgery (FGS) in high grade gliomas. However, fluorescence pattern and intensity is vari...
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Abstract
Introduction
Fine-needle aspiration (FNA) is commonly used to investigate lymphadenopathy of suspected metastatic origin. The current study aims to find the association be...
MicroRNAs in high-grade gliomas: What is their role?
MicroRNAs in high-grade gliomas: What is their role?
High-grade gliomas are malignant tumours of the central nervous system with poor overall survival. Equivalently, glioblastoma is one of the most devastating brain tumours. Treatmen...
Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist
Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist
Abstract
Learning Objectives
After completing this course, the reader will be able to:
Describe the known gene...
CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis
CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis
Background and ObjectivePossible treatment strategies for recurrent malignant gliomas include surgery, chemotherapy, radiotherapy, and combined treatments. Among different reirradi...

